Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

Health-care companies rose after strong earnings from one major drug maker. Novo Nordisk shares rose sharply after the Danish obesity-drug maker posted fourth-quarter Ozempic sales of $4.71 billion, ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

There is no sign of a slowdown in Johnston County's rapid growth, meaning things like cost of living and infrastructure are ...

Bernard Arnault is once again in charge of Europe's most valuable company. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Pictured is an insulin pen manufactured by the Novo Nordisk company on March 14, 2023, in Miami, Florida. The pharmacy benefit managers, the middlemen between manufacturers and insurance companies ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

While I don’t fully agree with this idea, Novo Nordisk (NVO) seems to be living up to it almost perfectly. Since 2022, the company has seen its share price increase by over 150% due to the ...

Therefore, NVO looks like a no-brainer 'Strong buy' opportunity for me. Novo Nordisk is a global healthcare company headquartered in Denmark. The product's portfolio is mainly focused on diabetes ...